Clinical trials: Esophagogastric Junction Disorder
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to explore the efficacy and safety of sintilimab combined with SOX versus SOX alone as adjuvant therapy for patients with pIIIC stage or dMMR/MSI-H pIIIA/IIIB stage gastric/gastroesophageal junction…
- Trial name
- NCT07492615
- Testing
- Sintilimab, S-1 & Oxaliplatin
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Fudan University
Gastric Cancer
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal…
- Trial name
- NCT01220934
- Where
- Germany
- Volunteers
- 443 people
- Sponsor
- Hoffmann-La Roche
Esophageal Neoplasms, Stomach Neoplasms
Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer
The aim of this study is to identify biomarkers predicting response or resistance factors of a targeted therapy with trastuzumab in advanced gastric cancer.
- Trial name
- VARIANZ (NCT02305043)
- Testing
- non-interventional
- Where
- Germany
- Volunteers
- 549 people
- Sponsor
- University of Leipzig
Gastric Cancer (GC)
Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer
The study aims to evaluate the efficacy and safety of the QL1706 combination with paclitaxel and bevacizumab in patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed first-line standard…
- Trial name
- NCT07045805
- Testing
- QL1706 combined with paclitaxel and bevacizumab
- Volunteers
- 66 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.
- Conditions
- Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer, Metastatic or Local Advanced GE Junction Cancer
- Trial name
- NCT00620607
- Testing
- huC242-DM4
- Where
- 4 sites in United States
- Sponsor
- ImmunoGen, Inc.
Esophageal Cancer, GastroEsophageal Cancer
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
This pilot phase II trial studies the therapeutic effects and side effects of CD40 agonistic monoclonal antibody APX005M when combined with chemotherapy and radiation therapy, and to see how well they work to reduce or remove…
- Trial name
- NCT03165994
- Testing
- APX005M, Radiation Therapy, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Apexigen America, Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT05002127
- Testing
- Evorpacept (ALX148), Trastuzumab, Ramucirumab
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 127 people
- Sponsor
- ALX Oncology Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable…
- Trial name
- NCT06155383
- Testing
- Capecitabine, oxaliplatin, Disitamab Vedotin
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Gastric Cancer, Esophagogastric Junction Cancer
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of ONO-4578 in combination nivolumab and chemotherapy in participants with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal…
- Conditions
- Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- NCT07818070
- Testing
- ONO-4578, Nivolumab, Oxaliplatin
- Volunteers
- 600 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastric Cancer, Esophageal Cancer
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer…
- Conditions
- Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
- Trial name
- NCT03044613
- Testing
- Nivolumab, Relatlimab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction…
- Trial name
- NCT02559687
- Testing
- pembrolizumab
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
The goal of this clinical trial is to evaluate postoperative adaptive adjuvant therapy in patients with gastric or gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy plus immunotherapy and radical…
- Trial name
- NCT07603349
- Testing
- Alternative Postoperative Treatment Regimen, Original Treatment Regimen, Postoperative Observation
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
Guanabana, known also as Graviola or Annona muricata is a tropical fruit which has been commonly used as complimentary/alternative medicine in Latin American countries.
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT04773769
- Testing
- Tea Made of Graviola Leaves
- Where
- Puerto Rico
- Volunteers
- 54 people
- Sponsor
- Auxilio Mutuo Cancer Center
Gastric Cancer, Gastric Adenocarcinoma
Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer
The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy
- Trial name
- LOTS (NCT04999332)
- Testing
- leucovorin, oxaliplatin, docetaxel, S-1
- Where
- 4 sites in Taiwan
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction
Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
The trial is designed to investigate differences in outcome of patients with esophageal adenocarcinoma and junctional adenocarcinoma treated with perioperative (neoadjuvant + adjuvant) chemotherapy (FLOT) plus surgical resection…
- Trial name
- ESOPEC (NCT02509286)
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 30 sites in Germany
- Volunteers
- 438 people
- Sponsor
- University Hospital Schleswig-Holstein
Advanced Solid Tumor, Gastric Cancer (GC)
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
This is an open-label, dose escalation, dose expansion and extension cohort phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of SYSA1801
- Conditions
- Advanced Solid Tumor, Gastric Cancer (GC), Gastroesophageal Junction (GEJ) Cancer, Pancreatic Cancer
- Trial name
- NCT05009966
- Testing
- SYSA1801 for injection
- Where
- China
- Volunteers
- 272 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Gastric Cancer, Gastric Adenocarcinoma
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
- Trial name
- NCT07529808
- Testing
- BHB810
- Where
- 3 sites in United States
- Volunteers
- 164 people
- Sponsor
- BigHat Biosciences, Inc.